aussie83
Forum Replies Created
-
Posts
-
Hello everyone,
An update since March this year. My mother-in-law has now had 3 cycles of gemcitabine plus cisplatin, with little response. The tumour stayed the same size. In late May, she had Sir-spheres inserted into her liver, and the PET scan to determine response will be in mid-July.
Meanwhile, she has had molecular testing results come back from Foundation One. Four genetic changes were identified (FDA-approved therapies in other tumour types are in parentheses):
– CDK4, amplification – equivocal (Palbociclib)
– ERBB2, amplification – equivocal (Ado-trastuzumab emtansine; Afatinib; Lapatinib; Pertuzumab; Trastuzumab)
– IDH1 – R132C (Azacitidine; Decitabine)
– APC – A2122_C2123insA (none)My MIL’s oncologist believes that the ERBB2 and IDH1 genetic changes hold the most potential for targeted therapy. I was wondering if anyone on this board also had one or both of these changes with their molecular testing? If so, which chemo agent(s) worked best?
Thanks in advance!
Kind regards,
Aussie83Hi Darla, Lainy, Genevieve, and Marion,
Thanks for your words of advice and good wishes. I’ve been looking around on this site (including using your links), and the CC Foundation and the members of this discussion board provide a wealth of information in this scary time.
The plan for my mother-in-law is to see what the CT scan shows after her first 2 cycles of chemo. Then, depending on what her surgeon says about operating or not, we will possibly seek a second opinion. My MIL and FIL are not keen to get a second opinion at this stage, and we want to respect their wishes.
We’ll ask her oncologist again about molecular testing.
I’ll definitely keep people updated on how things are going.
Aussie83
